CBP8
Phase 2Small molecule
CBP8 is one of 68 small molecule programs targeting Pulmonary Fibrosis. It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Idiopathic Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Esbriet
LLegacy Health System
Approved
Medrol
PfizerApproved
Viagra
VViatris Specialty LLC
Approved
Remodulin
United TherapeuticsApproved
Rapamune
PPrism Pharmaceuticals
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Rayos
RRoxane Laboratories
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Idiopathic Pulmonary Fibrosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CBP8. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMassachusetts General Hospital